HCG (Human Chorionic Gonadotropin): Complete Research Profile — LH-Mimetic Glycoprotein Hormone in Reproductive Biology, Hypogonadism, and Hormonal Research (2026)

HCG (Human Chorionic Gonadotropin): Complete Research Profile — LH-Mimetic Glycoprotein Hormone in Reproductive Biology, Hypogonadism, and Hormonal Research (2026)

Human chorionic gonadotropin (hCG) is a glycoprotein hormone produced by syncytiotrophoblast cells of the placenta during pregnancy and one of the most pharmacologically significant hormones in reproductive medicine research. Unlike most "peptides" studied in research contexts, hCG is technically a glycoprotein — a large, heavily glycosylated hormone (~37 kDa) composed of two non-covalently associated subunits. Yet its classification alongside research peptides reflects both its use in peptide supplier contexts and its fundamental role in reproductive biology research that overlaps significantly with peptide pharmacology.

hCG's primary research and clinical relevance derives from its ability to bind and activate the LH/hCG receptor (LHCGR) — the same G protein-coupled receptor activated by endogenous luteinizing hormone (LH). However, hCG's dramatically longer half-life (~37 hours vs. 25–30 minutes for LH) effectively makes it a "super-LH" from a pharmacological standpoint: it produces sustained receptor activation with longer-lasting downstream effects than LH pulses, making it operationally distinct despite activating the same receptor.

This profile covers hCG's structure, mechanism, reproductive biology research applications, research in hypogonadism models, PCT (post-cycle therapy) research context, and important regulatory notes for researchers.

This profile is provided for Research Use Only (RUO). All content is for educational and scientific research purposes.

---

Structural Identity

Full name: Human Chorionic Gonadotropin (hCG)

Class: Glycoprotein hormone; gonadotropin family

Structure: Heterodimer — alpha subunit (92 AA; shared with LH, FSH, TSH) + beta subunit (145 AA; hCG-specific with 24-AA C-terminal extension)

Molecular Weight: ~37,000–40,000 Da (varies significantly with glycosylation; glycans constitute ~30% of total mass)

Half-life: ~37 hours (circulating; vs. 25–30 minutes for LH)

Primary receptor: LH/hCG receptor (LHCGR; GPCR, Gs-coupled)

Natural source: Syncytiotrophoblast cells (pregnancy); also detectable in pituitary

Recombinant forms: Recombinant hCG (r-hCG; choriogonadotropin alfa) available as research reagent

The structural distinction between hCG and LH lies primarily in hCG's beta subunit, which contains a unique 24-amino acid C-terminal extension (CTE) relative to LH-beta. This CTE carries four O-linked oligosaccharide chains that are largely responsible for hCG's dramatically extended half-life: glycan chains shield hCG from hepatic clearance and reduce renal filtration relative to LH. The glycan coat constitutes approximately 30% of hCG's molecular mass — an unusually high carbohydrate content that gives hCG its characteristic pharmacokinetic profile.

---

Background: The Gonadotropin Family

Luteinizing Hormone (LH) and Its Role

LH is secreted by gonadotroph cells in the anterior pituitary in response to GnRH pulses from the hypothalamus. In males, LH acts on Leydig cells in the testes to stimulate testosterone synthesis via the LH/hCG receptor and the cAMP/PKA pathway. In females, the mid-cycle LH surge triggers ovulation and initiates corpus luteum formation, which subsequently produces progesterone to maintain early pregnancy.

Why hCG Substitutes for LH in Research and Medicine

hCG binds the same receptor (LHCGR) with similar or greater affinity to LH and activates the same intracellular signaling cascade (Gs/cAMP/PKA → steroidogenesis). The 37-hour half-life advantage means that a single dose of hCG can produce sustained LH receptor stimulation over 1–2 days, compared to the pulsatile nature of endogenous LH that requires frequent pituitary secretion pulses for maintained effect.

This property makes hCG practically superior to LH for most research and clinical applications requiring sustained gonadal stimulation: it can be administered less frequently, produces more consistent receptor occupancy, and is far more easily purified or synthesized than the rapidly degraded LH. hCG has functionally substituted for LH activity in clinical reproductive medicine since the 1950s.

---

Mechanism of Action

LH/hCG Receptor Binding

hCG binds to the LH/hCG receptor (LHCGR), a G protein-coupled receptor (Gs family) expressed on:

• •Leydig cells (testes) — primary site for testosterone synthesis
• •Granulosa and theca cells (ovaries) — estrogen and progesterone production
• •Luteal cells (corpus luteum) — progesterone maintenance during early pregnancy
• •Other tissues — thyroid (at high concentrations, cross-reacts with TSH receptor), uterus, placenta

Intracellular Signaling: cAMP/PKA Pathway

hCG binding to LHCGR activates Gαs, stimulating adenylyl cyclase to increase intracellular cAMP. Elevated cAMP activates protein kinase A (PKA), which phosphorylates steroidogenic acute regulatory protein (StAR) and downstream enzymes in the steroidogenesis pathway:

1. Cholesterol mobilization — StAR transports cholesterol from outer to inner mitochondrial membrane

2. Pregnenolone synthesis — CYP11A1 (cholesterol side-chain cleavage enzyme) converts cholesterol to pregnenolone

3. Testosterone synthesis (in Leydig cells) — pregnenolone is converted through progesterone, androstenedione, and finally testosterone via a series of enzymatic steps

The net result of hCG stimulation in males is increased intratesticular testosterone (ITT) and circulating testosterone production by Leydig cells.

hCG in Female Physiology

In early pregnancy, placental hCG production rescues the corpus luteum from luteal regression by providing continuous LH receptor stimulation. This maintains corpus luteum progesterone production, sustaining the uterine decidua and early embryo implantation environment until the placenta can assume progesterone production at 8–10 weeks gestation. The hCG surge in maternal serum and urine is the biochemical basis of pregnancy tests.

---

Research Applications

Reproductive Biology Research

hCG is a cornerstone reagent in reproductive biology research:

• •Superovulation protocols — in mouse, rat, and other model organisms, hCG administration following PMSG (pregnant mare serum gonadotropin, which has FSH-like activity) triggers synchronized ovulation for timed embryo collection — a fundamental technique in embryology, IVF model research, and transgenic animal generation
• •Corpus luteum function studies — investigating progesterone production, corpus luteum regression, and the hormonal dynamics of early pregnancy
• •Ovarian folliculogenesis — studying granulosa cell and theca cell biology, follicular maturation, and LH surge simulation
• •Fertilization research — timed ovulation induction creates predictable fertilization windows for reproductive timing studies

Leydig Cell Biology and Testicular Function Research

In male reproductive biology, hCG is the primary pharmacological tool for:

• •Stimulating testosterone biosynthesis — hCG administration to isolated Leydig cells or in vivo provides controlled, dose-dependent testosterone production for steroidogenesis pathway research
• •Leydig cell differentiation models — hCG stimulation is used to study Leydig cell maturation and steroidogenic enzyme expression
• •Intratesticular testosterone (ITT) studies — ITT is a critical parameter in spermatogenesis research; hCG is the primary tool for experimentally elevating ITT
• •Cryptorchidism models — hCG stimulation has been used in research on testicular descent mechanisms and hormonal control of cryptorchidism

Hypogonadotropic Hypogonadism Research

Hypogonadotropic hypogonadism (HH) — characterized by low testosterone due to insufficient LH/FSH from the pituitary — is a major focus of hCG research and clinical application. Research in this area includes:

• •Animal models of HH — GnRH-deficient rodent models (e.g., hpg mice) are used with hCG to rescue gonadal function, study downstream steroidogenesis, and characterize receptor-level responses
• •Combined gonadotropin therapy research — hCG typically used alongside FSH (or FSH analogs) to study the respective contributions of LH-receptor signaling and FSH-receptor signaling to spermatogenesis and Sertoli cell function
• •Clinical trial research context — hCG in combination with FSH has demonstrated efficacy in inducing spermatogenesis in HH patients in published clinical studies, providing translational context for preclinical research

Testosterone Replacement Therapy (TRT) Context

In males on exogenous testosterone, endogenous LH secretion is suppressed via negative feedback on the HPG (hypothalamic-pituitary-gonadal) axis. This suppression leads to:

• •Reduced intratesticular testosterone (despite normal or supraphysiological circulating levels)
• •Progressive testicular atrophy (reduced Leydig cell activity)
• •Impaired spermatogenesis (highly dependent on ITT)
• •Reduced fertility potential

hCG administration concurrently with exogenous testosterone can maintain LH receptor stimulation despite suppressed endogenous LH, preserving ITT and some degree of testicular volume and spermatogenic function. Research in this area investigates optimal hCG dosing with TRT protocols, fertility preservation strategies, and the relative contributions of ITT vs. circulating testosterone to testicular health.

Post-Cycle Research Context

Within anabolic steroid research and performance physiology contexts, hCG is studied as part of post-cycle therapy (PCT) protocols — interventions aimed at restoring endogenous HPG axis function following supraphysiological androgen exposure. Research in this area examines:

• •HPG axis recovery kinetics — how quickly LH, FSH, and testosterone recover post-cycle and whether hCG supplementation during or after cycles accelerates recovery
• •Testicular sensitivity — prolonged LH suppression may reduce Leydig cell responsiveness to endogenous LH upon recovery; hCG stimulation during cycles may maintain Leydig cell populations and sensitivity
• •Fertility outcomes — documenting spermatogenesis recovery and fertility restoration following steroid-induced suppression, with and without hCG-containing PCT protocols

---

Key Pharmacokinetic Parameters

---

hCG in Pregnancy Detection Research

hCG's unique production profile during pregnancy makes it the basis of all pregnancy testing:

• •hCG is detectable in maternal serum and urine within 6–12 days of implantation
• •Levels approximately double every 48–72 hours in normal early pregnancy (weeks 4–8)
• •Peak levels reach 100,000–200,000 mIU/mL around weeks 8–11 before declining
• •Abnormal hCG rise patterns (insufficient doubling, plateau, decline) are used in research models of early pregnancy loss, ectopic pregnancy, and gestational trophoblastic disease
• •Extremely elevated hCG (typically 100x normal) can cross-react with TSH receptors, producing gestational hyperthyroidism — studied in models of thyroid function during pregnancy

---

Regulatory and Classification Notes

Researchers working with hCG should be aware of significant regulatory variation by country and application context:

United States: Urinary hCG (e.g., Novarel, Pregnyl) and recombinant hCG (Ovidrel) are FDA-approved for specific clinical indications (ovulation induction, corpus luteum deficiency, cryptorchidism, hypogonadism). hCG for research use is available through scientific suppliers as a regulated research reagent. The FDA has restricted some hCG preparations for weight loss applications following review. hCG is listed as a controlled substance in sports anti-doping regulations (WADA).

WADA status: hCG is prohibited in-competition for male athletes under the WADA Prohibited List (Category S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics). This prohibition reflects its LH-mimetic capacity to stimulate endogenous testosterone production and mask anabolic steroid use during drug testing windows.

Research context: For research purposes, hCG is available as a purified urinary extract or recombinant product from scientific suppliers. Institutional review board (IRB) approval requirements apply for any human subjects research; animal research requires IACUC approval.

---

Comparison: hCG vs. Related Research Compounds

---

Research Considerations and Limitations

Batch variability: Urinary-derived hCG preparations have inherent batch-to-batch variability in glycosylation patterns and specific biological activity. Recombinant hCG (r-hCG) offers more consistent glycosylation for research requiring high reproducibility.

TSH receptor cross-reactivity: At high concentrations (relevant to gestational trophoblastic disease models or high-dose in vivo experiments), hCG can activate TSH receptors, confounding thyroid function readouts. Include appropriate controls in experimental designs involving high hCG concentrations.

Temperature sensitivity: As a glycoprotein, hCG is more temperature-sensitive than simple peptides. Cold chain maintenance during shipping and storage is essential; exposing preparations to elevated temperatures or repeated freeze-thaw cycles degrades activity.

Immunogenicity: In repeated administration in vivo studies, antibody development against hCG can occur, potentially confounding later time points. This is particularly relevant for chronic administration protocols.

Regulatory compliance: Researchers must ensure their hCG supply is obtained through legitimate scientific channels with appropriate documentation. hCG's WADA-prohibited status means researchers in sports science or anti-doping research contexts face specific documentation requirements.

---

Quality Standards and Sourcing

• •Biological activity: Expressed as IU (International Units); potency testing against WHO reference standard is the key quality metric for hCG — molecular weight alone does not capture activity
• •Sterility and endotoxin: Critical for in vivo studies; request sterility and LAL endotoxin test data
• •Source type: Urinary vs. recombinant; for high-reproducibility research, recombinant hCG (choriogonadotropin alfa) is preferred
• •Storage: Lyophilized hCG is stable at -20°C; reconstituted preparations should be aliquoted to avoid freeze-thaw cycles; protect from prolonged room temperature exposure
• •Documentation: Given regulatory sensitivities, ensure complete chain of custody documentation and research-use declarations from your supplier

---

Storage and Handling

• •Lyophilized: -20°C protected from light and moisture; stable for years when properly stored
• •Reconstituted: Dissolve in sterile water for injection or bacteriostatic water (benzyl alcohol); stable at 4°C for 60 days or -20°C for up to 1 year (varies by formulation)
• •Working concentrations: Widely variable by application — from nanogram/mL concentrations for cell-based assays to IU doses for in vivo reproductive biology protocols
• •Handling note: Minimize mechanical agitation; glycoproteins are susceptible to denaturation via shear

---

Key References

• •Cole LA. (2010). Biological functions of hCG and hCG-related molecules. Reprod Biol Endocrinol 8:102. doi:10.1186/1477-7827-8-102
• •Physiology, Chorionic Gonadotropin. StatPearls. NCBI Bookshelf
• •Human Chorionic Gonadotropin. StatPearls. NCBI Bookshelf
• •Casarini L et al. (2018). The biology of gonadotropins. J Endocrinol Invest 41(5):509–521.
• •Rastrelli G et al. (2014). Testosterone and sexual function in men. Maturitas 79(2):123–131.
• •Coviello AD et al. (2005). Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression. J Clin Endocrinol Metab 90(5):2595–2602.
• •Bhasin S et al. (2018). Testosterone therapy in men with hypogonadism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 103(5):1715–1744.

---

Further Reading:

• •Irisin (FNDC5): Complete Research Profile — The Exercise-Induced Myokine in Metabolic, Neuroprotection, and Bone Biology Research (2026)
• •PYY (Peptide YY): Complete Research Profile — The Gut Satiety Hormone in Appetite Regulation and Obesity Research (2026)
• •Testagen (KEDG Tetrapeptide): Complete Research Profile — Khavinson Testicular & Reproductive Bioregulator (2026)
• •Glutathione (GSH): Complete Research Profile — Master Antioxidant Tripeptide in Redox Biology, Cancer, Neurodegeneration, and Cellular Defense Research
• •Reconstitution Calculator
• •Peptide Stack Builder

---

This article is for educational and scientific research purposes only. HCG is a regulated substance in many jurisdictions and is prohibited in athletic competition under WADA regulations. Nothing in this profile constitutes medical advice or encouragement for non-research use.